Researchers in this study are trying to find out more about the mechanisms of action of a drug called olaparib. olaparib is a PARP inhibitor which is a targeted treatment for ovarian cancer. Researchers wish to find out why some women's ovarian cancer responds well to olaparib while other ovarian cancers don't. This information will help them to be…

The purpose of this study is to help researchers better understand how niraparib is used in the UK and how well it's tolerated by those taking it.Niraparib is a type of drug known as a PARP inhibitor. PARP inhibitors are a relatively new class of drugs known as targeted therapies. In this study the researchers wish to collect real time information …

Researchers are conducting the PROMPT trial to see if the study drug (pembrolizumab) can be used as a maintenance treatment to slow the growth/return of cancer after treatment with paclitaxel (standard chemotherapy drug). Normally, after receiving paclitaxel, patients are observed without treatment as maintenance treatment is not standard for this …